Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles virus vaccine live + mumps virus vaccine live + rubella virus vaccine live
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
The **measles virus vaccine live + mumps virus vaccine live + rubella virus vaccine live** is a combination vaccine used for active immunization against measles, mumps, and rubella in individuals 12 months of age and older. Each component is a live, attenuated virus that stimulates the body's immune system to produce protective antibodies, thereby preventing these diseases. This vaccine is crucial in global public health efforts to eliminate measles and rubella and reduce mumps outbreaks. It does *not* contain varicella vaccine (see MMRV for that variant). Approved formulations (including M-M-R II and PRIORIX) are administered in two doses, typically at ages 12–15 months and 4–6 years. The vaccine works by inducing an immune response to viral envelope antigens, leading to long-lasting immunity for measles and rubella, although mumps immunity may diminish over time. The primary indication is prevention of measles, mumps, and rubella[2][3][6][8].
- Brand names
- M-M-R IIPRIORIX
- Other names
- MMR vaccinemeasles-mumps-rubella vaccinemeasles virus vaccine live + mumps virus vaccine live + rubella virus vaccine live
02
Targets
HCV E1 (Hepatitis C virus envelope glycoprotein E1)MV-H (Measles virus hemagglutinin protein)
Beyond the preview
Go deeper on measles virus vaccine live + mumps virus vaccine live + rubella virus vaccine live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles virus vaccine live + mumps virus vaccine live + rubella virus vaccine live.